Wednesday, July 8, 2026

Patent intelligence · US

US 9095624

Modular transport platform for targeted delivery of therapeutic agents

granted A61KA61K41/0071A61K47/6415A61K47/642
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 9
Applicant portfolio 9
Patent details — US 9095624
Jurisdiction
US
Status
granted
Grant date
Aug 4, 2015
Expiration
Jul 30, 2035
Claims
15
CPC classes
A61K, A61K41/0071, A61K47/6415, A61K47/642
View on Google Patents ↗

Quick answer

US 9095624 (Modular transport platform for targeted delivery of therapeutic agents) is held by Contango Partners Group, Inc.. Status: granted. Granted Aug 4, 2015. Expires Jul 30, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
15
CPC classes
A61K, A61K41/0071, A61K47/6415, A61K47/642, A61K47/6445, A61K51/081

More from Contango Partners Group, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12403137

    Compounds and methods of use

    Tango Therapeutics, Inc. · Expires Aug 28, 2045

    granted
  2. US 12304907

    Compounds and methods of use

    Tango Therapeutics, Inc. · Expires May 15, 2045

    granted
  3. US 12264154

    Compounds and methods of use

    Tango Therapeutics, Inc. · Expires Mar 27, 2045

    granted
  4. US 12043607

    HDAC inhibitors and therapeutic use thereof

    Tango Therapeutics, Inc. · Expires Jul 18, 2044

    granted
  5. US 11999727

    Compounds and methods of use

    Tango Therapeutics, Inc. · Expires May 30, 2044

    granted
  6. US 11986471

    Compounds and methods of use

    Tango Therapeutics, Inc. · Expires May 16, 2044

    granted
  7. US 11492350

    Compounds and methods of use

    Tango Therapeutics, Inc. · Expires Nov 3, 2042

    granted
  8. US 11077101

    Compounds and methods of use

    Tango Therapeutics, Inc. · Expires Jul 29, 2041

    granted

Frequently asked questions

What is US patent 9095624?

US 9095624 (Modular transport platform for targeted delivery of therapeutic agents) is held by Contango Partners Group, Inc.. Status: granted. Granted Aug 4, 2015. Expires Jul 30, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9095624?

Contango Partners Group, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.

When does US 9095624 expire?

Our index shows an expiration date of Jul 30, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.